title: Practical management of anticoagulation, bleeding and blood product support for cardiac surgery. Part two: transfusion issues.
abstract: We summarise recent advances in transfusion medicine applicable to cardiac surgery and cardiac transplantation. It is important that clinicians know the risks of blood transfusion in Australia. They should also be aware of the different types of transfusion reaction so that there is early recognition and investigation. Blood conservation strategies including acceptance of normovolaemic anaemia in clinically stable patients are important in reducing the requirement for red cell transfusion. Cytomegalovirus (CMV) seronegative blood products are recommended for heart transplant recipients with no evidence of prior CMV infection. Leucodepletion of units of unknown CMV status reduces the risk of CMV infection and are an acceptable alternative when seronegative units are unavailable. Leucodepletion of cellular blood products has been shown to reduce infection rates postoperatively in a large trial involving cardiac surgical patients. Further studies are needed to confirm this promising finding. Irradiation of blood products eliminates the risk of transfusion-associated graft versus host disease. Routine preoperative screening for cold agglutinins is no longer recommended.
authors.affiliation: Australian Red Cross Blood Service, Adelaide, South Australia.
authors.forename: Kathryn L
authors.initials: KL
authors.lastname: Robinson
authors.forename: Silvana F
authors.initials: SF
authors.lastname: Marasco
authors.forename: Alison M
authors.initials: AM
authors.lastname: Street